MarketCap
Facebook
X
Telegram
PetIQ Operating Income | PETQ
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income PetIQ
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.1 M | -20.2 M | 15.9 M | -3.19 M | -3.14 M | 7.75 M | 13.3 M | 702 K | 3.57 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 37.1 M | -20.2 M | 5.75 M |
Quarterly Operating Income PetIQ
| 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25.6 M | 24.3 M | 9.36 M | 18.7 M | 18.9 M | - | -42.5 M | 11.4 M | 9.4 M | - | -3.18 M | 16.5 M | 7.13 M | - | -3.29 M | 3.69 M | 464 K | -12.6 M | -4.36 M | 8.99 M | 4.87 M | -4.85 M | 6.56 M | 9.38 M | -3.08 M | 42 K | 1.78 M | 6.67 M | 4.8 M | 116 K | -1.78 M | 659 K | 1.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 25.6 M | -42.5 M | 3.85 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
HEXO Corp.
HEXO
|
-1.07 B | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-373 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Assertio Holdings
ASRT
|
-21.5 M | - | - | $ 150 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-103 M | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
-18 M | - | - | $ 5.07 M | USA |
 |
Zomedica Corp.
ZOM
|
-84.4 M | - | -0.21 % | $ 98 M | USA |
 |
Aurora Cannabis
ACB
|
4.95 M | $ 4.46 | 13.78 % | $ 245 M | Canada |
 |
Bausch Health Companies
BHC
|
1.81 B | $ 5.89 | 1.55 % | $ 2.18 B | Canada |
 |
Canopy Growth Corporation
CGC
|
-162 M | $ 0.88 | 1.04 % | $ 262 M | Canada |
 |
China Pharma Holdings
CPHI
|
-3.24 M | $ 0.65 | 1.57 % | $ 2.79 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.37 M | $ 7.09 | 0.27 % | $ 105 M | USA |
 |
Cronos Group
CRON
|
-17.4 M | $ 3.25 | 0.78 % | $ 1.25 B | Canada |
 |
Emergent BioSolutions
EBS
|
100 M | $ 7.24 | 14.29 % | $ 387 M | USA |
 |
Evolus
EOLS
|
-32.7 M | $ 7.47 | 4.62 % | $ 482 M | USA |
 |
Harrow Health
HROW
|
30.5 M | $ 30.58 | 0.33 % | $ 1.12 B | USA |
 |
OrganiGram Holdings
OGI
|
-35.7 M | $ 0.94 | 0.18 % | $ 89.6 M | Canada |
 |
Organogenesis Holdings
ORGO
|
44.7 M | $ 1.29 | 2.19 % | $ 163 M | USA |
 |
Pacira BioSciences
PCRX
|
19.2 M | $ 25.05 | 0.42 % | $ 1.12 B | USA |
 |
Perrigo Company plc
PRGO
|
-1.12 B | $ 14.44 | 1.3 % | $ 2 B | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 3.48 | 0.68 % | $ 137 M | USA |
 |
Rockwell Medical
RMTI
|
-4.69 M | $ 8.23 | 0.93 % | $ 296 M | USA |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 5.03 | 1.07 % | $ 251 M | USA |
 |
Solid Biosciences
SLDB
|
-179 M | $ 7.06 | 3.07 % | $ 618 M | USA |
 |
Sundial Growers
SNDL
|
-6.35 M | $ 1.25 | 0.81 % | $ 323 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-2.46 M | $ 1.22 | 0.81 % | $ 2.05 M | USA |
 |
Tilray
TLRY
|
-2.28 B | $ 3.72 | 3.05 % | $ 3.31 B | Canada |
 |
TherapeuticsMD
TXMD
|
-4.39 M | $ 2.01 | 1.46 % | $ 23.3 M | USA |
 |
Veru
VERU
|
-24.8 M | $ 2.55 | 1.59 % | $ 37.3 M | USA |
 |
Viatris
VTRS
|
-2.66 B | $ 17.62 | 0.11 % | $ 20.2 B | USA |
 |
cbdMD
YCBD
|
-2.16 M | $ 0.43 | 0.29 % | $ 1.73 M | USA |
 |
OptiNose
OPTN
|
-16.3 M | - | - | $ 1.08 B | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
-5.2 M | - | - | $ 36.6 M | USA |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-18.9 M | - | - | $ 50.1 M | USA |